Skip to main content


Neuren Pharmaceuticals Ltd (ASX:NEU) CEO Jon Pilcher speaks with Proactive following the news that its North America partner Acadia Pharmaceuticals has received US Food and Drug Administration approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients. Acadia expects DAYBUE to be available by the end of April 2023.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.